A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Status:
Recruiting
Trial end date:
2025-10-21
Target enrollment:
Participant gender:
Summary
This study will look at how well CagriSema compared to Tirzepatide helps people lower their
body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that
combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors.
Participant will get injections once a week throughout the treatment period. Participant will
inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper
arm. After a first low dose, the study medicine will be gradually increased until reaching
the planned dose (2.4 mg CagriSema or 15 mg Tirzepatide). The study will last for about one
and a half year for each participant.